EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 4 (Avril 2023) Med Sci (Paris), 39 4 (2023) 335-343 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 4, Avril 2023
Page(s) 335 - 343
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023008
Publié en ligne 24 avril 2023
  1. Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019 ; 96 : 1048–1050. [CrossRef] [PubMed] [Google Scholar]
  2. Fried LF, Folkerts K, Smeta B, et al. Targeted literature review of the burden of illness in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care 2021; 27 : S168–77. [CrossRef] [PubMed] [Google Scholar]
  3. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98 : S1–115. [CrossRef] [PubMed] [Google Scholar]
  4. Chang TI, Li S, Chen S-C, et al. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2013 ; 61 : S4–11. [CrossRef] [PubMed] [Google Scholar]
  5. Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 2021; 143 : 1157–72. [CrossRef] [PubMed] [Google Scholar]
  6. Fang M, Wang D, Coresh J, et al. Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. N Engl J Med 2021; 384 : 2219–28. [CrossRef] [PubMed] [Google Scholar]
  7. Barrera-Chimal J, Bonnard B, Jaisser F. Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annu Rev Physiol 2022; 84 : 585–610. [CrossRef] [PubMed] [Google Scholar]
  8. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42 : 152–61. [CrossRef] [PubMed] [Google Scholar]
  9. Barrera-Chimal J, Lima-Posada I, Bakris GL, et al. Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects. Nat Rev Nephrol 2022; 18 : 56–70. [CrossRef] [PubMed] [Google Scholar]
  10. Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primer 2015 ; 1 : 15018. [CrossRef] [Google Scholar]
  11. DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol 2021; 17 : 319–34. [CrossRef] [PubMed] [Google Scholar]
  12. Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 2010 ; 6 : 319–330. [CrossRef] [PubMed] [Google Scholar]
  13. Barrera-Chimal J, Jaisser F. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes Obes Metab 2020; 22 Suppl 1 : 16–31. [CrossRef] [PubMed] [Google Scholar]
  14. Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev 2016 ; 68 : 49–75. [CrossRef] [PubMed] [Google Scholar]
  15. Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol 2022; 179 : 3220–34. [CrossRef] [PubMed] [Google Scholar]
  16. Bauersachs J, Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl 2022; 12 : 19–26. [CrossRef] [Google Scholar]
  17. Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic Activity. Hypertens Dallas Tex 1979 ; 2018 : 71 : 599–608. [Google Scholar]
  18. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007 ; 3 : 486–492. [CrossRef] [PubMed] [Google Scholar]
  19. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 ; 359 : 1565–1576. [CrossRef] [PubMed] [Google Scholar]
  20. Kakar F, Weiss NS, Strite SA. Non-contraceptive estrogen use and the risk of gallstone disease in women. Am J Public Health 1988 ; 78 : 564–566. [CrossRef] [PubMed] [Google Scholar]
  21. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021; 9 : 653–62. [CrossRef] [PubMed] [Google Scholar]
  22. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 ; 341 : 709–717. [CrossRef] [PubMed] [Google Scholar]
  23. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 ; 348 : 1309–1321. [CrossRef] [PubMed] [Google Scholar]
  24. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013 ; 34 : 2453–2463. [CrossRef] [PubMed] [Google Scholar]
  25. Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 2015 ; 314 : 884–894. [CrossRef] [PubMed] [Google Scholar]
  26. Filippatos G, Anker SD, Böhm M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 2016 ; 37 : 2105–2114. [CrossRef] [PubMed] [Google Scholar]
  27. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383 : 2219–29. [CrossRef] [PubMed] [Google Scholar]
  28. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385 : 2252–63. [CrossRef] [PubMed] [Google Scholar]
  29. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43 : 474–84. [CrossRef] [PubMed] [Google Scholar]
  30. Agarwal R, Anker SD, Filippatos G, et al. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant 2022; 37 : 1261–9. [CrossRef] [PubMed] [Google Scholar]
  31. Agarwal R, Joseph A, Anker SD, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol 2022; 33 : 225–37. [CrossRef] [PubMed] [Google Scholar]
  32. Thompson S, James M, Wiebe N, et al. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol 2015 ; 26 : 2504–2511. [CrossRef] [PubMed] [Google Scholar]
  33. Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open 2019 ; 2 : e1918169. [CrossRef] [PubMed] [Google Scholar]
  34. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol 2021; 6 : 148–58. [CrossRef] [PubMed] [Google Scholar]
  35. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015 ; 372 : 222–231. [CrossRef] [PubMed] [Google Scholar]
  36. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015 ; 372 : 211–221. [CrossRef] [PubMed] [Google Scholar]
  37. Barrera-Chimal J, Gerarduzzi C, Rossignol P, et al. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci 2022; 136 : 1005–17. [CrossRef] [PubMed] [Google Scholar]
  38. Neuen BL, Oshima M, Agarwal R, et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 2022; 145 : 1460–70. [CrossRef] [PubMed] [Google Scholar]
  39. van der Beek AB, Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol 2022; 18 : 294–306. [CrossRef] [PubMed] [Google Scholar]
  40. Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. J Am Soc Nephrol 2022; 33 : 1569–80. [CrossRef] [PubMed] [Google Scholar]
  41. Green JB, Mottl AK, Bakris G, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 2022; gfac198. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.